LT4247361T - Kompleksinė terapija kepenų ligai gydyti - Google Patents
Kompleksinė terapija kepenų ligai gydytiInfo
- Publication number
- LT4247361T LT4247361T LTEPPCT/EP2021/081838T LTEP2021081838T LT4247361T LT 4247361 T LT4247361 T LT 4247361T LT EP2021081838 T LTEP2021081838 T LT EP2021081838T LT 4247361 T LT4247361 T LT 4247361T
- Authority
- LT
- Lithuania
- Prior art keywords
- treatment
- combination therapy
- liver disease
- liver
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20306394.6A EP4000616A1 (en) | 2020-11-17 | 2020-11-17 | Combination therapy for the treatment of a liver disease |
| PCT/EP2021/081838 WO2022106412A1 (en) | 2020-11-17 | 2021-11-16 | Combination therapy for the treatment of a liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT4247361T true LT4247361T (lt) | 2025-05-12 |
Family
ID=73554407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2021/081838T LT4247361T (lt) | 2020-11-17 | 2021-11-16 | Kompleksinė terapija kepenų ligai gydyti |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240016807A1 (lt) |
| EP (2) | EP4000616A1 (lt) |
| JP (2) | JP2023544220A (lt) |
| KR (2) | KR102843766B1 (lt) |
| CN (2) | CN116490189A (lt) |
| CA (1) | CA3199014A1 (lt) |
| DK (1) | DK4247361T3 (lt) |
| ES (1) | ES3030638T3 (lt) |
| FI (1) | FI4247361T3 (lt) |
| HR (1) | HRP20250622T1 (lt) |
| HU (1) | HUE071223T2 (lt) |
| LT (1) | LT4247361T (lt) |
| PL (1) | PL4247361T3 (lt) |
| PT (1) | PT4247361T (lt) |
| RS (1) | RS66744B1 (lt) |
| SI (1) | SI4247361T1 (lt) |
| SM (1) | SMT202500154T1 (lt) |
| WO (1) | WO2022106412A1 (lt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022122014A1 (zh) | 2020-12-11 | 2022-06-16 | 苏州科睿思制药有限公司 | Lanifibranor的晶型及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59426B1 (sr) | 2014-06-13 | 2019-11-29 | Inventiva | Ppar jedinjenja za upotrebu u tretmanu fibroznih bolesti |
| US20180021341A1 (en) * | 2015-01-09 | 2018-01-25 | Gilead Apollo, Llc | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
| IL268751B (en) * | 2017-03-13 | 2022-08-01 | Genfit | Pharmaceutical preparations for combined treatment |
| US12150945B2 (en) * | 2018-07-20 | 2024-11-26 | Lipocine Inc. | Liver disease |
| FR3084254B1 (fr) | 2018-07-27 | 2020-10-23 | Inventiva | Derives deuteres du lanifibranor |
-
2020
- 2020-11-17 EP EP20306394.6A patent/EP4000616A1/en not_active Withdrawn
-
2021
- 2021-11-16 JP JP2023528978A patent/JP2023544220A/ja active Pending
- 2021-11-16 SI SI202130294T patent/SI4247361T1/sl unknown
- 2021-11-16 RS RS20250418A patent/RS66744B1/sr unknown
- 2021-11-16 CN CN202180079437.7A patent/CN116490189A/zh active Pending
- 2021-11-16 KR KR1020247027665A patent/KR102843766B1/ko active Active
- 2021-11-16 PT PT218055523T patent/PT4247361T/pt unknown
- 2021-11-16 HU HUE21805552A patent/HUE071223T2/hu unknown
- 2021-11-16 FI FIEP21805552.3T patent/FI4247361T3/fi active
- 2021-11-16 CN CN202510506770.1A patent/CN120459105A/zh active Pending
- 2021-11-16 CA CA3199014A patent/CA3199014A1/en active Pending
- 2021-11-16 SM SM20250154T patent/SMT202500154T1/it unknown
- 2021-11-16 LT LTEPPCT/EP2021/081838T patent/LT4247361T/lt unknown
- 2021-11-16 PL PL21805552.3T patent/PL4247361T3/pl unknown
- 2021-11-16 HR HRP20250622TT patent/HRP20250622T1/hr unknown
- 2021-11-16 DK DK21805552.3T patent/DK4247361T3/da active
- 2021-11-16 ES ES21805552T patent/ES3030638T3/es active Active
- 2021-11-16 US US18/037,123 patent/US20240016807A1/en active Pending
- 2021-11-16 WO PCT/EP2021/081838 patent/WO2022106412A1/en not_active Ceased
- 2021-11-16 EP EP21805552.3A patent/EP4247361B1/en active Active
- 2021-11-16 KR KR1020237019728A patent/KR102697824B1/ko active Active
-
2024
- 2024-12-20 JP JP2024225537A patent/JP2025060758A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL4247361T3 (pl) | 2025-06-23 |
| FI4247361T3 (fi) | 2025-05-13 |
| RS66744B1 (sr) | 2025-05-30 |
| KR20230110541A (ko) | 2023-07-24 |
| CN116490189A (zh) | 2023-07-25 |
| WO2022106412A1 (en) | 2022-05-27 |
| EP4247361A1 (en) | 2023-09-27 |
| SMT202500154T1 (it) | 2025-05-12 |
| KR20240131458A (ko) | 2024-08-30 |
| KR102697824B1 (ko) | 2024-08-23 |
| EP4000616A1 (en) | 2022-05-25 |
| HRP20250622T1 (hr) | 2025-07-18 |
| KR102843766B1 (ko) | 2025-08-07 |
| SI4247361T1 (sl) | 2025-06-30 |
| PT4247361T (pt) | 2025-04-21 |
| DK4247361T3 (da) | 2025-05-05 |
| US20240016807A1 (en) | 2024-01-18 |
| EP4247361B1 (en) | 2025-03-05 |
| CN120459105A (zh) | 2025-08-12 |
| HUE071223T2 (hu) | 2025-08-28 |
| ES3030638T3 (en) | 2025-07-01 |
| JP2023544220A (ja) | 2023-10-20 |
| JP2025060758A (ja) | 2025-04-10 |
| CA3199014A1 (en) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281256A (en) | Combined treatment for the treatment of triple-negative breast cancer | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| GB202005852D0 (en) | Therapeutic compounds | |
| GB2587172B (en) | Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer | |
| SG11202103141YA (en) | Combination therapy for the treatment of cancer | |
| IL307465A (en) | Combined therapies for cancer treatment | |
| GB202218860D0 (en) | Therapeutic agents | |
| IL284162A (en) | Integrated healing for cancer treatment | |
| EP4069251A4 (en) | SALTS AND POLYMORPHS OF CETHROMYCIN FOR THE TREATMENT OF DISEASES | |
| GB202005863D0 (en) | Therapeutic compounds | |
| SMT202500154T1 (it) | Terapia di combinazione per il trattamento di una malattia epatica | |
| GB202210731D0 (en) | Therapeutic agents | |
| GB202103640D0 (en) | Therapeutic compounds | |
| GB202218846D0 (en) | Therapeutic agents | |
| GB202103642D0 (en) | Therapeutic compounds | |
| ZA202207243B (en) | A pharmaceutical combination for the treatment of a cancer | |
| IL320482A (en) | Combination therapy for cancer treatment | |
| IL321362A (en) | Therapeutic compounds | |
| GB202110728D0 (en) | Therapeutic compounds | |
| ZA202300725B (en) | A prescription for the treatment of liver cancer | |
| GB202302445D0 (en) | Therapeutic compounds | |
| GB202217955D0 (en) | Therapeutic compounds | |
| GB202101577D0 (en) | Therapeutic compounds | |
| GB202101574D0 (en) | Therapeutic compounds | |
| GB202207050D0 (en) | Therapeutic compounds |